Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a long-term (104 weeks) Phase 3 clinical study which showed that the investigational compound dapagliflozin added to metformin sustained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) from 52-weeks to 104-weeks, in adults with type 2 diabetes when compared to glipizide (a common sulphonylurea treatment) added to metformin. The proportion of patients with adverse events was similar between the treatment groups... 
More...
More...